Resveratrol attenuates efavirenz-induced hepatic steatosis and hypercholesterolemia in mice by inhibiting pregnane X receptor activation and decreasing inflammation

• DOI: 10.1016/j.nutres.2023.09.006
• Publication Date: 2023-09-17T21:38:21Z
• Authors: Xingguo Miao; Hui Ye; Xiaoya Cui; Xiuxiu Guo; Feifei Su
• Keywords: Pregnane X receptor; Steatosis; Efavirenz; Dyslipidemia

Efavirenz (EFV), a widely prescribed antiviral medication, has been implicated in dyslipidemia and can activate the pregnane X receptor (PXR), leading to hepatic steatosis hypercholesterolemia mice. Resveratrol (RES) ameliorate functions as partial PXR agonist, capable of mitigating expression induced by other agonists. Therefore, we hypothesized that RES could attenuate EFV-induced downregulating suppressing inflammatory cytokine production. Here, conducted an vivo study involving 6-week-old male mice, which were divided into 4 groups for 7-day intervention: control (carrier solution), EFV (80 mg/kg), (50 + groups. Serum tissue samples collected assess cholesterol triglyceride concentrations. Hepatic lipid accumulation was evaluated through hematoxylin-eosin oil red O staining. Polymerase chain reaction western blot performed quantify factors, lipogenic gene, expression. Our results indicated droplet reduced group compared with group. Similarly, expressions factors attenuated relative Furthermore, counteracted upregulation lipid-metabolizing enzymes at both transcriptional protein levels. Importantly, downregulated Conclusively, our findings suggest effectively mitigates inhibiting activation decreasing inflammation.